K. Kracht

AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.

B. Rini, C. Szczylik, B. Escudier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.

T. Mok, F. Kabbinavar, Y. Hei, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

P. Ganly, K. Kracht, V. Charu, 2005 .

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

A. Ravaud, M. Fishman, R. Ramlau, 2012, Cancer.

Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study.

A. Ravaud, M. Atkins, P. Tomczak, 2012 .

Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety

Jeremy D. Jokinen, Valerie C. Simmons, K. Kracht, 2019, Therapeutic innovation & regulatory science.

Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

T. Mok, F. Kabbinavar, R. Sikorski, 2010 .